Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRĪ±)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Gynecol Oncol. 2024;185:186-193 - PMID: 38447347 - DOI: 10.1016/j.ygyno.2024.01.045
1
CSV